FIELD: biotechnologies.
SUBSTANCE: invention relates to crystal anhydrous δ-modification of N-(2-chlorine-6-methylphenyldiazomethane)-2-[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pirimidinyl]amino]-5-thiazolcarboxamide, characterized by the following set of interplanar distances (d, E) and the intensities corresponding to them (Irel., %): 9.637-69.1%; 7.928-29.2%; 6.415-100%; 5.819-39.4%; 5.529-3.0%; 4.941-27.2%; 4.887-5.6%; 4.549-72.6%; 4.092-3.8%; 4.037-3.2%; 3.847-35.0%; 3.782-5.8%; 3.751-5.2%; 3.642-3.9%; 3.607-2.7%; 3.442-16.6%; 3.383-3.0%; 3.183-27.4%; 3.122-21.7%; 3.099-5.6%; 2.958-6.9%; 2.905-3.4%; 2.763-7.5%; 2.757-7.8%; 2.694-9.2%; 2.551-12.6%; 2.516-2.6%; 2.463-3.9%; 2.292-3.9%; 2.270-5.0%; 2.137-4.0%; 2.112-3.5%; 2.024-3.7%; 1.906-3.4%; 1.867-3.0%; 1.780-6.0%. Crystal anhydrous delta modification of N-(2-chlorine-6-methylphenyldiazomethane)-2-[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pirimidinyl]amino]-5-thiazolcarboxamide is obtained by dissolving of N-(2-chlorine-6-methylphenyldiazomethane)-2-[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pirimidinyl]amino]-5-thiazolcarboxamide in organic solvent. Crystallites are extracted from the solution using the solvent switch method of replacement or by cooling with subsequent filtering, washing, the crystallites are frozen and subjected to sublimation drying during 22-27 hours at the final temperature on the product 25°C minimum. Crystal anhydrous δ-modification of N-(2-chlorine-6-methylphenyldiazomethane)-2-[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pirimidinyl]amino]-5-thiazolcarboxamide, which is characterized by inhibitory activity with reference to the tyrosine kinase, for preparation of pharmaceutical composition for treatment of immunological and oncological diseases.
EFFECT: increase of biological activity.
5 cl, 6 dwg, 3 tbl, 2 ex
| Title |
Year |
Author |
Number |
| CRYSTALLINE γ-MODIFICATION OF N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINOLINE AMINE OF BIS (4-METHYLBENZENESULFONATE) MONOHYDRATE, METHOD OF ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION BASED THEREON |
2016 |
- Mikhajlov Oleg Rostislavovich
- Uvarov Nikolaj Aleksandrovich
- Malin Aleksandr Aleksandrovich
|
RU2603943C1 |
| CRYSTALLINE β-MODIFICATION OF 4-[4-({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYL}AMINO)PHENOXY]-N-METHYL-PYRIDINE-2-CARBOXAMIDE OF p-TOLUENE SULPHONATE, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION BASED THEREON |
2015 |
- Mikhajlov Oleg Rostislavovich
- Uvarov Nikolaj Aleksandrovich
- Malin Aleksandr Aleksandrovich
|
RU2568638C1 |
| CRYSTALLINE ANHYDROUS γ-MODIFICATION OF 4-(3'-CHLOR-4'-FLUORANILINO)-7-METHOXY-6-(3-MORPHOLINOPROPOXY)QUINAZOLINE, METHOD FOR PRODUCING IT AND BASED PHARMACEUTICAL COMPOSITION |
2014 |
- Malin Aleksandr Aleksandrovich
- Mikhajlov Oleg Rostislavovich
- Uvarov Nikolaj Aleksandrovich
|
RU2577518C2 |
| NANOSIZE WEAKLY CRYSTALLINE MODIFICATION OF 4-METHYL-N-[3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL]-3-[(4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO]BENAZAMIDE HYDROCHLORIDE MONOHYDRATE, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION BASED THEREON |
2013 |
- Malin Aleksandr Aleksandrovich
- Mikhajlov Oleg Rostislavovich
- Uvarov Nikolaj Aleksandrovich
|
RU2551359C1 |
| CRYSTALLINE H-MODIFICATION OF 2-AMINO-2-(2-(4-OCTYLPHENYL) ETHYL)PROPANE-1,3-DIOLE HYDROCHLORIDE, METHOD FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION BASED THEREON |
2016 |
- Mikhajlov Oleg Rostislavovich
- Uvarov Nikolaj Aleksandrovich
- Malin Aleksandr Aleksandrovich
|
RU2627691C1 |
| CRYSTALLINE β-MODIFICATION OF 3-(4-AMINO-1-OXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE, METHOD OF ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION BASED THEREON |
2016 |
- Mikhajlov Oleg Rostislavovich
- Uvarov Nikolaj Aleksandrovich
- Malin Aleksandr Aleksandrovich
|
RU2616976C1 |
| CRYSTALLINE β-MODIFICATION OF N-(3-ETHYLPHENYL)-6,7-BIS(2 METHOXYETHOXY)QUINAZOLINE-4-AMINE HYDROCHLORIDE, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION BASED THEREON |
2015 |
- Mikhajlov Oleg Rostislavovich
- Uvarov Nikolaj Aleksandrovich
- Malin Aleksandr Aleksandrovich
|
RU2610337C1 |
| CRYSTALLINE Μ-MODIFICATION OF 1-[(3R)-3-[4-AMINO-3-(4-PHENOXY-PHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]-1-PIPERIDYL]-2-PROPENYL-1-ONE, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION BASED THEREON |
2018 |
- Mikhajlov Oleg Rostislavovich
- Uvarov Nikolaj Aleksandrovich
- Malin Aleksandr Aleksandrovich
|
RU2711106C2 |
| CRYSTALLINE ε-MODIFICATION OF N-[2-(DIETHYLAMINO)ETHYL]-5-[(Z)-(5-FLUOR-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)METHYL]-2,4-DIMETHYL-1H-PYRROL-3-CARBOXAMIDE MALATE, METHOD FOR PRODUCING SAME AND BASED PHARMACEUTICAL COMPOSITION |
2014 |
- Malin Aleksandr Aleksandrovich
- Mikhajlov Oleg Rostislavovich
- Uvarov Nikolaj Aleksandrovich
|
RU2567535C1 |
| WEAKLY CRYSTALLISED β-MODIFICATION OF (S)-ISOPROPYL 2-((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-(2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)-(PHENOXY)PHOSPHORYLAMINO)PROPANOATE, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION BASED THEREON |
2017 |
- Mikhajlov Oleg Rostislavovich
- Uvarov Nikolaj Aleksandrovich
- Malin Aleksandr Aleksandrovich
|
RU2656228C9 |
